- Home
- SNDR vs MIRM Comparison
SNDR vs MIRM Comparison
Compare SNDR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDR | MIRM |
|---|---|---|
| Founded | 1935 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.2B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNDR | MIRM |
|---|---|---|
| Price | $33.61 | $98.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $27.83 | ★ $119.85 |
| AVG Volume (30 Days) | 561.3K | ★ 635.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $5,674,300,000.00 | $19,138,000.00 |
| Revenue This Year | $5.11 | $26.22 |
| Revenue Next Year | $6.05 | $22.04 |
| P/E Ratio | $86.28 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $63.23 |
| 52 Week High | $39.27 | $130.00 |
Technical Indicators
Market Signals| Indicator | SNDR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 43.13 |
| Support Level | $26.68 | $97.49 |
| Resistance Level | $36.79 | $105.20 |
| Average True Range (ATR) | 0.96 | 3.27 |
| MACD | -0.16 | 0.45 |
| Stochastic Oscillator | 7.31 | 36.65 |
Price Performance
Historical ComparisonAbout SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.